Argus•January 20, 2021

SUPN: Raising target price to $31.00

Symbols

SUPN

Sector(s)

Healthcare

Rating

Premium

Current Price

$26.87

Price Target

$NaN

Earnings Estimate

Premium

Summary

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders.

Premium

Subscribe to Yahoo Finance Premium for full access

Read the latest independent research including analyst forecasts, ratings on the US economy, and more. Get individual company and overall sector level recommendations.

Try Premium FREE

Actions

Download Full Report

Related Reports

LCI: Rating increased to a HOLD
Feb 24, 2021 •
LCI
CORT: Lowering target price to $29.00
Feb 24, 2021 •
CORT
EGRX: Raising target price to $49.00
Feb 24, 2021 •
EGRX
Analyst Report: Eli Lilly and Company
Feb 17, 2021 •
LLY
LCI: What does Argus have to say about LCI?
Feb 17, 2021 •
LCI

View more related reports